Shanghai Kechow Pharma, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-06-18
- Employees
- 51
- Market Cap
- -
- Website
- http://www.kechowpharma.com
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008106
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008119
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05900219
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05331105
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05263453
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT05233332
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
HL-085 in NRAS-mutated Advanced Melanoma
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05217303
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03990077
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, China
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03976050
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
🇺🇸Livestrong Cancer Institute, Dell Medical School, The University of Texas at Austin, Austin, Texas, United States
Study of HL-085 in NRAS Mutant Advanced Melanoma
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03973151
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath